116 related articles for article (PubMed ID: 25778496)
1. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer.
Klopper J; Kane M; Jimeno A; Sams S; French J; Pike L; Tompkins K; Haugen B
Thyroid; 2015 May; 25(5):563-4. PubMed ID: 25778496
[No Abstract] [Full Text] [Related]
2. The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life.
Dueren C; Dietlein M; Luster M; Plenzig F; Steinke R; Grimm J; Groth P; Eichhorn W; Reiners C
Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):513-9. PubMed ID: 19856258
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor effect of UFT against differentiated thyroid cancer].
Suzumura K; Koike A; Naruse T; Matsumoto K; Nagata H; Kojima T; Kanemitsu T; Katoh K
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2485-9. PubMed ID: 7944495
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of gefitinib in patients with advanced thyroid cancer.
Pennell NA; Daniels GH; Haddad RI; Ross DS; Evans T; Wirth LJ; Fidias PH; Temel JS; Gurubhagavatula S; Heist RS; Clark JR; Lynch TJ
Thyroid; 2008 Mar; 18(3):317-23. PubMed ID: 17985985
[TBL] [Abstract][Full Text] [Related]
5. Motesanib diphosphate in progressive differentiated thyroid cancer.
Sherman SI; Wirth LJ; Droz JP; Hofmann M; Bastholt L; Martins RG; Licitra L; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Schlumberger MJ;
N Engl J Med; 2008 Jul; 359(1):31-42. PubMed ID: 18596272
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.
Matuszczyk A; Petersenn S; Bockisch A; Gorges R; Sheu SY; Veit P; Mann K
Horm Metab Res; 2008 Mar; 40(3):210-3. PubMed ID: 18348081
[TBL] [Abstract][Full Text] [Related]
7. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
8. Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials.
Tyagi P
Clin Lung Cancer; 2005 Jul; 7(1):17-9. PubMed ID: 16098239
[No Abstract] [Full Text] [Related]
9. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
[TBL] [Abstract][Full Text] [Related]
10. [Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma].
Reverter JL; Colomé E
Endocrinol Nutr; 2011 Feb; 58(2):75-83. PubMed ID: 21247815
[TBL] [Abstract][Full Text] [Related]
11. Role of 131I in the treatment of well differentiated thyroid cancer.
Woodrum DT; Gauger PG
J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
[TBL] [Abstract][Full Text] [Related]
12. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
13. [Mycosis fungoid treated with oral bexarotene: study of 13 cases].
Roche Gamón E; Pérez Ferriols A; Vilata Corell JJ; Alegre de Miquel V
Med Clin (Barc); 2007 Nov; 129(17):677. PubMed ID: 18005638
[No Abstract] [Full Text] [Related]
14. Folliculotropic mycosis fungoides responding to bexarotene gel.
Walling HW; Swick BL; Gerami P; Scupham RK
J Drugs Dermatol; 2008 Feb; 7(2):169-71. PubMed ID: 18335654
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous CD30 positive anaplastic large cell lymphoma--report of a case treated with bexarotene.
Oliveira A; Fernandes I; Alves R; Lima M; Selores M
Leuk Res; 2011 Nov; 35(11):e190-2. PubMed ID: 21764128
[No Abstract] [Full Text] [Related]
16. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
[TBL] [Abstract][Full Text] [Related]
17. In search of a real "targeted" therapy for thyroid cancer.
Brose MS
Clin Cancer Res; 2012 Apr; 18(7):1827-9. PubMed ID: 22451620
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal treatment of differentiated thyroid neoplasms].
Ferrini O; Biassoni P; Bagnasco M; Santaniello B
Arch Maragliano Patol Clin; 1978; 34(1):37-46. PubMed ID: 583618
[No Abstract] [Full Text] [Related]
19. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
20. Rapid Control of T3 Thyrotoxicosis in Patients with Metastatic Follicular Thyroid Cancer Treated with Lenvatinib.
Danilovic DL; de Camargo RY; Castro G; Papadia C; Marui S; Hoff AO
Thyroid; 2015 Nov; 25(11):1262-4. PubMed ID: 26357945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
